Heavy policy promulgated the pharmaceutical industry opportunities and challenges co-exist
With the social and economic development, the advancement of science and technology, the increase of government investment and the improvement of residents 'health awareness, people pay more and more attention to the prevention and treatment of various diseases. Residents' demand for medical products has fundamentally drove the rapid development of the pharmaceutical industry. At the same time, the growing demand for health has also put forward higher technical and innovation requirements for the pharmaceutical industry in our country.
According to the data from National Bureau of Statistics of China, during the "Eleventh Five-year Plan" period, the compound annual growth rate of the revenue from main business of pharmaceutical manufacturing industry above designated size in China reached 23.31%, entering the "12th Five-Year Plan" period. With the expansion of health insurance coverage and urban residents' The new rural cooperative medical insurance recipients continued to improve the standard of subsidies for all groups of our country's medical insurance levels are gradually increased, the pharmaceutical industry is still maintained rapid growth momentum.
Prospective Industry Research Institute released the "Pharmaceutical Industry Market Outlook and Investment Analysis Report" data show that China's pharmaceutical manufacturing January-September 2017 total main business revenue 2.171530 trillion yuan, an increase of 12.10%, compared with the year 2016 January-September 10.00% up 2.1 percentage points; total profit of 241.99 billion yuan, an increase of 18.40%, compared with 13.90% in January-September 2016 rose 4.5 percentage points.
The total revenue and profit of the main business of pharmaceutical manufacturing industry increased year on year
From the perspective of the circulation of pharmaceutical products, the concentration and circulation efficiency of the drug circulation industry have all increased under the guidance of the Outline of the National Drug Distribution Industry Development Plan (2011-2015), the sales volume and economic efficiency have been steadily increasing, The overall trend of sustained and good development.
Over the past two years, the pharmaceutical industry has introduced and implemented heavyweights in succession. It has faced new opportunities and challenges in areas such as drug approval, production, distribution, payment and treatment as well as pharmaceuticals, distribution, medical equipment and services. From the beginning of 2012, with the price cuts of base medicine in various provinces, the reform of the payment mode of medical insurance and restrictions on the implementation of policy changes such as the use of antibiotics, the growth of the pharmaceutical industry began to enter the downward trajectory.
Revenue growth in other segments of the pharmaceutical manufacturing industry dropped to about 10% in 2015 and profit growth picked up in 2015. However, the profit growth of the pharmaceutical and pharmaceutical industry continued to decline in 2015, indicating that the industry was reviewed Policy reform, a new round of bidding and sales costs increase and other factors affect the performance growth under pressure.